Related Experiment Video
Updated: Apr 17, 2026
An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
Published on: January 9, 2020
Tamoxifen resistance: from cell culture experiments towards novel biomarkers
Norbert Nass1, Thomas Kalinski1
1Department of Pathology, Otto von Guericke University Magdeburg, Leipziger Str. 44, D 39120 Magdeburg, Germany.
Abstract:
Tamoxifen is still the most frequently used antiestrogen for the treatment of patients with premenopausal, estrogen receptor positive breast cancer. However, in 20-30% of these cases, tamoxifen therapy fails due to an existing or developing resistance. The prediction of tamoxifen resistance by appropriate biomarker analysis and the development of novel therapies for tamoxifen resistance in premenopausal breast cancer is, therefore, an important goal of ongoing research. Tamoxifen resistance is associated with altered estrogen receptor expression especially on the plasma membrane, including the alternative G-protein coupled receptor GPR-30 (GPER) and estrogen receptor splice products, such as ERα36. Tamoxifen resistant cells often use alternative pathways to promote proliferation in the absence of genomic estrogen signaling. These pathways involve the epidermal growth factor EGF, the inflammation associated transcription factor NF-κB- and the IGF-1 pathway. Tamoxifen resistant mamma carcinoma cell lines are useful models to understand tamoxifen resistance in-vitro and to search for prognostic or predictive biomarkers. Furthermore, such cell lines can be used to identify potential targets for therapy.
Insights
Tamoxifen therapy fails in 20-30% of premenopausal breast cancer patients due to resistance. Understanding tamoxifen resistance mechanisms and identifying biomarkers are crucial for developing new treatments.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Tamoxifen is a primary antiestrogen therapy for premenopausal estrogen receptor-positive breast cancer.
- Therapy failure occurs in 20-30% of cases due to tamoxifen resistance.
- Identifying mechanisms and biomarkers for tamoxifen resistance is critical.
Purpose of the Study:
- To investigate the molecular mechanisms underlying tamoxifen resistance in breast cancer.
- To explore the role of altered estrogen receptor expression and alternative signaling pathways in resistance.
- To identify potential biomarkers and therapeutic targets for tamoxifen-resistant breast cancer.
Main Methods:
- Utilizing tamoxifen-resistant breast cancer cell lines as in-vitro models.
- Analyzing altered estrogen receptor expression, including GPER and ERα36.
- Investigating alternative proliferation pathways such as EGF, NF-κB, and IGF-1.
Main Results:
- Tamoxifen resistance is linked to altered estrogen receptor expression (e.g., GPER, ERα36).
- Resistant cells activate alternative signaling pathways (EGF, NF-κB, IGF-1) for proliferation.
- Tamoxifen-resistant cell lines serve as valuable tools for research.
Conclusions:
- Understanding tamoxifen resistance mechanisms is essential for improving breast cancer treatment.
- Biomarker analysis can aid in predicting and managing tamoxifen resistance.
- Further research using cell line models can identify novel therapeutic strategies.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012